| Name | Title | Contact Details |
|---|
The Supreme Cannabis Company (TSXV: FIRE) (OTCQX: SPRWF) (FRA: 53S1) is a Canadian publicly traded company committed to providing premium brands and products that proudly reflect its consumers, people and uniquely innovative culture. The Company`s portfolio includes its wholly-owned subsidiary and award-winning brand, 7ACRES. 7ACRES is a federally licensed producer of cannabis operating inside a 342,000-square-foot facility in Kincardine, Ontario. 7ACRES is dedicated to providing consumers with a premium-quality product that recognizes its customers are informed, discerning and value a brand and culture that aligns with their principles. 7ACRES brand success has been reflected in its "Brand of the Year" award win at the 2018 Canadian Cannabis Awards, and in provincial supply agreements where 7ACRES` product is consistently listed in the highest brand category available to recreational consumers. The Company`s growing portfolio also includes an equity investment and long-term global distribution partnership with Lesotho-based Medigrow for the exporting of medical-grade cannabis oil. The Supreme Cannabis Company has been a leading innovator in the sector including the design of growing facilities and development of operational excellence metrics. We are confident that together with our flagship brand, proprietary technology and products, truly unique culture, and industry-leading team, we will deliver our shareholders consistent long-term value creation.
PharmaLinkFHI (PharmaLink) is the first full-service Clinical Research Organization (CRO) to integrate clinical and technological expertise in managing Phase I-IV clinical trials online in real time. Biopharmaceutical and medical device organizations
Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.
Norwich Pharmaceuticals, Inc. is a Norwich, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mission Pharmacal is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.